Physician profile
Anthony C Stumbo
NPI 1780769422
$2,356.67
in general payments reported to CMS, 2019-2025
29 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $290 · 2021: $261 · 2022: $364 · 2023: $391 · 2024: $349 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,067.61 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $345.28 | 2019-2024 | Repatha, Otezla |
| Lilly USA, LLC | $219.12 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.69 | 2020-2025 | Jardiance |
| Abbvie INC. | $168.17 | 2021-2025 | Qulipta |
| Astrazeneca Pharmaceuticals LP | $144.96 | 2019-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $127.33 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $126.43 | 2024-2025 | |
| Glaxosmithkline, LLC. | $101.38 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Daiichi Sankyo INC. | $84.39 | 2020-2023 | Injectafer |
| Pfizer INC. | $83.73 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $83.09 | 2020-2024 | |
| Abbott Laboratories | $78.22 | 2024-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $73.68 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $69.67 | 2021-2023 | Korlym |
| Phathom Pharmaceuticals, INC. | $59.43 | 2024-2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $55.11 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $51.18 | 2019-2023 | Lifevest |
| Otsuka America Pharmaceutical, INC. | $34.24 | 2023-2024 | Rexulti |
| Medtronic Minimed, INC. | $32.90 | 2019-2020 | |
| Esperion Therapeutics, INC. | $28.98 | 2021 | |
| Dexcom, INC. | $28.73 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $25.39 | 2019-2022 | |
| Allergan, INC. | $23.57 | 2019-2020 | |
| Tonix Medicines, INC. | $22.02 | 2025 | Tonmya |
| Paratek Pharmaceuticals, INC. | $19.99 | 2023 | Nuzyra |
| La Jolla Pharmaceutical Company | $18.26 | 2023 | Giapreza |
| Exact Sciences Corporation | $17.32 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.72 | 2024 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $14.69 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Stumbo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.